Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2017 08:00 ET | Source: Advaxis

Advaxis Appoints Anthony Lombardo as Chief Business Officer

PRINCETON, N.J., April 19, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Anthony A. Lombardo, an industry...
March 27, 2017 08:00 ET | Source: Advaxis

Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac

PRINCETON, N.J., March 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at...
March 23, 2017 08:00 ET | Source: Advaxis

EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer

PRINCETON, N.J., March 23, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced the European Medicines Agency (EMA) issued...
March 15, 2017 07:00 ET | Source: Advaxis

Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGO’s Annual Meeting on Women’s Cancer

- Achieved primary objective of 12-month survival rate, demonstrating axalimogene filolisbac is an active therapy in metastatic cervical cancer - Unprecedented 12-month survival rate for metastatic...
March 13, 2017 08:00 ET | Source: Advaxis

Advaxis to Present at the 2017 Barclays Global Healthcare Conference

PRINCETON, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Sara Bonstein, Chief Financial...
March 07, 2017 08:00 ET | Source: Advaxis

Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical

PRINCETON, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Al Blunt, M.D., has joined...
March 06, 2017 06:00 ET | Source: Advaxis

Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO

PRINCETON, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug...
March 02, 2017 08:00 ET | Source: Advaxis

Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

PRINCETON, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, will host a Research Reception during the...
February 27, 2017 08:00 ET | Source: Advaxis

Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy

PRINCETON, N.J., and HAMILTON, Bermuda, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on...
February 06, 2017 08:00 ET | Source: Advaxis

Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer

PRINCETON, N.J., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient has been...